A case report of toxic epidermal necrolysis (TEN) in a patient with COVID-19 treated with hydroxychloroquine: are these two partners in crime?Case Report Published on 2020-10-062022-11-01 Journal: Clinical and Molecular Allergy : CMA [Category] COVID-19, [키워드] Activation Adverse Adverse Drug Reaction (ADR) ALDEN Algorithm Algorithm Antibiotics Atypical Blister calculated cardiometabolic Case report caused clinical evidence COVID 19 COVID-19 COVID-19 positive patient Cutaneous detect Dexamethasone drug epidermal extension highest Hydroxychloroquine immune system knowledge lesion less low-molecular-weight-heparin Manifestations mucous membrane Necrolysis off-label Other outcome pandemic Paracetamol Patient patient with COVID-19 pharmacovigilance potassium canrenoate Rash reaction regimen respiratory retrieved SARS-CoV- 2 SCORTEN Score Severe Cutaneous Adverse Reactions (SCAR) Stevens–Johnson Syndrome (SJS) syndrome the patient total body Toxic Epidermal Necrolysis (TEN) toxicities treated virus widespread [DOI] 10.1186/s12948-020-00133-6 PMC 바로가기 [Article Type] Case Report
Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: a case series기계적으로 환기되는 COVID-19 환자에게 분무된 인라인 기관내 도르나제 알파 및 알부테롤: 사례 시리즈Short Report Published on 2020-09-292022-08-13 Journal: Molecular Medicine [Category] 임상, [키워드] Administered administration albuterol analyzed ARDS case sery clinical Clinical data clinical trials collected contribute coronavirus COVID-19 COVID-19 patients demographic discharged distal DNA DNase 1 Dornase alfa Dosing Efficacy electronic medical record electronic medical records FIVE fraction hospital in-line nebulizer system mechanically ventilated mechanically ventilated patient mechanically ventilated patients medical records membrane Mortality mucoid sputum mucopurulent secretion Mucopurulent secretions nebulized NET NETs neutrophil Neutrophil extracellular trap Neutrophil extracellular traps oxygen Oxygen requirement Patient Registered required Result SARS-CoV-2 serum severe COVID-19 single-center sputum Tolerability toxicities Toxicity Trial veno-venous extracorporeal membrane oxygenation ventilated patient Ventilation viscosity VV-ECMO was reduced with COVID-19 [DOI] 10.1186/s10020-020-00215-w PMC 바로가기 [Article Type] Short Report
How to follow-up a patient who received tocilizumab in severe COVID-19: a case reportCase Report Published on 2020-08-272022-10-31 Journal: European Journal of Medical Research [Category] COVID-19, MERS, [키워드] addition approach ARDS Case report change characterized Chloroquine Clinical deterioration Clinical improvement Complete COVID-19 current Cytokine storm Deterioration Effectiveness elevated Follow-up healthy hyperinflammation hypoxic IL-6 receptor immunomodulating agent infections Infectious disease Initially initiated Long-term follow-up long-term treatment lung lung tissue magnitude mechanical ventilation mechanism organ injury overlapping Patient procedure Prognosis radiological remained Research SARS-CoV-2 serum severe COVID-19 Standard Standard of care suggested survivor Survivors TCZ therapy Tocilizumab toxicities Toxicity treated Treatment Warsaw [DOI] 10.1186/s40001-020-00438-x PMC 바로가기 [Article Type] Case Report
Management of Patients With Hematologic Malignancies During the COVID-19 Pandemic: Practical Considerations and Lessons to Be LearnedOncology Published on 2020-08-142022-10-31 Journal: Frontiers in Oncology [Category] COVID-19, [키워드] absence absorbed affected avoidance Blood cancers CAR T-cell Care complex consolidation COVID-19 COVID-19 pandemic curative diagnostic effective element European greater HCT Health hematologic malignancies Hematologic malignancy increasingly Laboratory lesson leukemia lymphoma lymphopenia molecular test Myeloma myelosuppression offer pandemic Patients with cancer predict required risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 positive patient selected severe disease surgical telehealth therapy toxicities treat Treatment Vaccine vulnerable patient while [DOI] 10.3389/fonc.2020.01439 PMC 바로가기 [Article Type] Oncology
AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trialAGILE-ACCORD: COVID-19 치료를 위한 여러 후보 약제의 최적 용량, 안전성 및 효능을 결정하기 위한 무작위, 다기관, 원활한, 적응 I/II상 플랫폼 연구: 무작위 플랫폼에 대한 연구 프로토콜의 구조화된 요약 재판Letter Published on 2020-06-192022-08-13 Journal: Trials [Category] SARS, 임상, [키워드] 9-point ordinal scale acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adaptive added Adult patients Adverse adverse events agent Anti-viral treatment approval Bayesian Blinding candidate Candidates clinical Clinical improvement cloud Cohort cohorts Combination Common Terminology Criteria Community community setting comparator contributing to coronavirus COVID-19 COVID-19 infection CST cytokine cytokine release death defined determine disease dissemination dose EDC Efficacy Efficacy and safety element eligibility criteria eligible England EudraCT evaluated expected for inclusion futility GRADE group hospitalised hospitalised patient Hospitalization in some include Infection intubation Ireland laboratory-confirmed later phase limit Mask Master protocol mechanical ventilation mechanism mechanism of action multi-arm multicentre Multiple nasal prongs non-invasive ventilation North number objective open Open-label opens optimal dose Ordinal Scale organ Other outcome oxygen oxygen saturation oxygen) participant Patient patient population patients peripheral capillary Peripheral capillary oxygen saturation phase Phase I/II Placebo platform Platform study Platform trial Population Prevent progression of disease promise protocol randomisation randomised Rave recruited recruitment Regulatory required respiratory Safety Sample size SARS-CoV-2 SARS-COV-2 infection seamless setup severe acute respiratory syndrome Coronavirus severe disease shown SOC Specific Stage Standard Standard of care status Study protocol the WHO toxicities Toxicity Treatment treatment of COVID-19 Trial Trial registration Ventilation Viral Viral load viral replication website WHO working [DOI] 10.1186/s13063-020-04473-1 PMC 바로가기 [Article Type] Letter
Disentangling the Hypothesis of Host Dysosmia and SARS-CoV-2: The Bait Symptom That Hides Neglected Neurophysiological RoutesPhysiology Published on 2020-06-052022-10-31 Journal: Frontiers in Physiology [Category] COVID-19, [키워드] Affect arise Blood Brain Central nervous system clinician consequence coronavirus COVID-19 death dysosmia effort excluded healthcare healthy Hospitalized Host host pathogen interactions human host hypoxia individuals infection with SARS-CoV-2 infections local inflammation lung nasal Neglected nervous system Neuroinvasive Neurological symptoms neuronal Neuropsychiatric occur olfactory olfactory bulb other coronavirus other coronaviruses outbreak pandemic Patient Premature proliferation public health researcher Respiratory failure route SARS-CoV-2 shown sick Smell subjects susceptible individuals Symptom target the disease therapy tissue toxicities Viral pneumonia viral proliferation virulence virus while Wuhan, China [DOI] 10.3389/fphys.2020.00671 PMC 바로가기 [Article Type] Physiology